www.fdanews.com/articles/101767-eisai-bioarctic-neuroscience-ink-alzheimer-s-agreement
Eisai, BioArctic Neuroscience Ink Alzheimer's Agreement
December 4, 2007
Japanese drugmaker Eisai and Sweden’s BioArctic Neuroscience have signed a license agreement for BAN2401, a novel humanized monoclonal antibody being developed as a treatment for Alzheimer’s disease.
Under the agreement, Eisai will obtain global rights to develop and market BAN2401, which is in preclinical development, Eisai said.
The drug’s development comes as a result of a 2005 research alliance between Eisai and BioArctic.